After Hours
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility.
Stocks Info
ACAD belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. The current market capitalization of Acadia Pharmaceuticals Inc is $2.40B. A total of 1.42 million shares were traded on the day, compared to an average of 1.70M shares.
In the most recent transaction, Schneyer Mark C. sold 2,708 shares of ACAD for 14.82 per share on Apr 08 ’25. After the transaction, the EVP, CHIEF FINANCIAL OFFICER now owns 59,456 company shares. In a previous transaction on Apr 08 ’25, Kihara James sold 1,028 shares at 14.82 per share. ACAD shares that PRINCIPAL ACCOUNTING OFFICER owns now total 22,257.
Among the insiders who sold shares, Kihara James disposed of 1,095 shares on Mar 26 ’25 at a per-share price of $17.05. This resulted in the PRINCIPAL ACCOUNTING OFFICER holding 21,275 shares of ACAD after the transaction. In another insider transaction, Schneyer Mark C. sold 3,171 shares at $17.05 per share on Mar 26 ’25. Company shares held by the EVP, CHIEF FINANCIAL OFFICER now total 56,889.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. In terms of 52-week highs and lows, ACAD has a high of $20.68 and a low of $13.40.
As of this writing, ACAD has an earnings estimate of -$0.0 per share for the current quarter. EPS was calculated based on a consensus of 15.0 estimates, with a high estimate of $0.28 per share and a lower estimate of -$0.59.
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. ACAD’s latest balance sheet shows that the firm has $520.71M in Cash & Short Term Investments as of fiscal 2021. There were $64.43M in debt and $96.07M in liabilities at the time. Its Book Value Per Share was $4.40, while its Total Shareholder’s Equity was $540.89M.
Analysts Opinion
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ACAD is Buy with a score of 4.00.
